Published in Hepatitis Weekly, June 17th, 2002
"These positive interim results continue to reinforce that PEGASYS combined with ribavirin is highly effective and acceptably tolerated among patients with difficult to treat disease who are in high need of therapy," said the study's principal investigator, Dr. Eberhard Renner, Head of Hepatology at the University...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.